Latest Cancer News
TUESDAY, June 19 (HealthDay News) -- Giving four weeks of a targeted drug before starting chemotherapy improved response rates in a small group of patients with advanced pancreatic cancer, University of Michigan researchers report.
The results are "very, very preliminary," said Dr. Jay Brooks, chairman of hematology/oncology at Ochsner Health System in Baton Rouge, La., but may show "a modicum of progress at least in understanding the biology of the disease. Pancreatic cancer is an incredibly difficult cancer to treat."
The drug, GDC-0449, targets the Sonic Hedgehog signaling pathway, which is switched on when cancer is present.
The researchers hypothesized that giving GDC-0449 before chemotherapy might improve the efficacy of chemotherapy and their early findings indicate that may be the case.
GDC is already used for basal cell carcinoma under the name Erivedge (vismodegib).
Twenty-one patients with previously untreated metastatic pancreatic cancer first received four weeks of GDC, given in pill form once a day, then chemotherapy with the drug gemcitabine.
Biopsies taken both before GDC was given and three weeks later showed tumor shrinkage in five patients while another four patients achieved "stable" disease, meaning the tumor was not shrinking or growing.
The drug was most effective in patients who initially had high levels of Hedgehog expression.
Hedgehog levels are notably elevated in cancer stem cells. These are "a subset of cells identified in many cancers, including pancreatic cancer, which are believed not only to drive tumor growth but which are also particularly resistant to standard therapies like chemotherapy and radiation," explained study author Dr. Edward Kim, a medical oncologist at the University of Michigan Comprehensive Cancer Center in Ann Arbor.
"The response rate to gemcitabine was what one would expect," said conference chairman Dr. Daniel Von Hoff, physician-in-chief and distinguished professor at the Translational Genomic Research Institute and professor of medicine at the Mayo Clinic in Rochester, Minn.
That was somewhat disappointing, but "the good news is that the inhibitors do not add any kind of substantial toxicities whatsoever," he said. "The next step is a randomized trial."
A second study being presented at the conference, this one conducted in mice, found a protein that makes pancreatic cancer cells stubbornly refuse to respond to treatment.
Blocking the protein, known as RLIP76, in mice with pancreatic cancer resulted in "complete regression" in the tumors, said study senior author Dr. Sanjay Awasthi, a professor of medical oncology and therapeutics research, and diabetes, endocrinology and metabolism at City of Hope Cancer Center in Duarte, Calif.
RLIP76 transports killer chemicals from chemotherapy drugs and radiation out of the cells before they can do their jobs. There tends to be more RLIP76 in pancreatic cancer cells than in healthy human cells.
Awasthi said he and his colleagues hope to move forward with this molecule, possibly as both an anti-diabetes and anti-cancer drug.
Awasthi is the founder of Terapio, the company that makes the recombinant RLIP76 protein to treat radiation poisoning. Terapio is not involved with any application of the protein to treat cancer.
Findings presented at medical meetings are typically considered preliminary until published in a peer-reviewed journal.
Copyright © 2012 HealthDay. All rights reserved.